Has Raymond Zimmer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $216,393 in general payments to Raymond Zimmer, MD across 10 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raymond Zimmer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raymond Zimmer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raymond Zimmer, MD

Cardiovascular Disease · Beverly Hills, CANPI 1013150499

Payments from drug & device makers

$216,393in general payments, 2019–2025

Across 10 payments — averaging $21,639 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sensible Medical Innovations Ltd$216K
Biosense Webster, Inc.$230
Medtronic$166
Boston Scientific$123
GE HealthCare$78
Novartis$58
plus $21 from 1 others

What the payments were for

Food & beverage$675100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sensible Medical Innovations Ltd	1	$215,718
Biosense Webster, Inc.	2	$230
Medtronic	1	$166
Boston Scientific	1	$123
GE HealthCare	2	$78
Novartis	2	$58
Esperion Therapeutics, Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,393 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$308,543

Medicare patients

882

Services billed

2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	332	$353,725
XareltoRivaroxaban	137	$151,269
Repatha SureclickEvolocumab	109	$112,376
EntrestoSacubitril/Valsartan	84	$98,403
FarxigaDapagliflozin Propanediol	84	$78,082
Repatha PushtronexEvolocumab	39	$33,884
Praluent PenAlirocumab	27	$32,567
OzempicSemaglutide	17	$18,946
BrilintaTicagrelor	25	$16,814
DapagliflozinDapagliflozin Propanediol	20	$10,947
Rosuvastatin Calcium	587	$10,409
Metoprolol Succinate	338	$4,564
Amiodarone Hcl	91	$3,432
Atorvastatin Calcium	435	$3,171
Olmesartan Medoxomil	123	$2,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
NovartisEntresto	$58	$98,40384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Beverly Hills

Andriana NikolovaBeverly Hills$980K
Ronald KarlsbergBeverly Hills$883K
Bruce SamuelsBeverly Hills$598K
Charles SwerdlowBeverly Hills$562K
Ted LoveHillsborough$102.8M
Matthew BudoffTorrance$11.3M
Lori DanielsSan Diego$10.2M
Paul KurthSanta Barbara$6.1M
Michael BlumSan Francisco$5.5M
Tony ChouSan Francisco$5.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →